mRNA Cancer Vaccines Show 5-Year Melanoma Results Amid US Funding Cuts

Executive Briefing

• Moderna and Merck report mRNA cancer vaccine kept melanoma patients cancer-free for five years in landmark trial
• Reveals early promise in pancreatic cancer, with 7 of 8 immune responders still alive up to six years post-treatment
• Estimates project personalized mRNA cancer vaccine market could reach $8.5 billion annually by 2034
• Contrasts progress with HHS cutting $500 million in mRNA research while NCI funds $200 million public-private partnership
• Warns scientists that fragmenting mRNA research could cede technological leadership to other countries